Global C-19 Vaccination Goal and framework for Action

September 2021
RECAP: objective of updated COVID-19 Global Vaccination Strategic Vision

1. Inform country targets and global vaccination goals for 2022 in light of key uncertainties

2. Promote equitable approach to vaccination globally, as part of broader pandemic control strategy

3. Inform global policymaking & access efforts, investments by financial/donor institutions, R&D groups & manufacturers, and country planning & work
**RECAP: Global C19 Vaccination Strategy included broad consultation**

**Governance**
- SAGE (with engagement of STAG-IH & EC as needed)

**Task Team**
- (10 people)
  - Working team of technical experts representing a few key stakeholders
  - Sub-workstreams on different technical matters leveraging existing modelling groups

**Ad hoc Strategy Group**
- (40 people)
  - Broader group providing strategic direction
  - Representatives of all key stakeholders

**Wider stakeholder consultation** incl. Member States Consultation

**Key Stakeholders**
- **Europe**
  - Norway Amb. GH
  - FCDO
  - eCDC
  - SEEHN
- **Asia**
  - China CDC
  - India
  - Thai MoPH
- **Americas**
  - PAHO RF
  - US CDC
  - US HHS
  - Mexico (Instituto del Seguro Social)
- **Africa**
  - Afro CDC
  - African Development Bank
  - AU
  - Nigeria CDC
  - Uganda VRI
- **Australia/Oceania**
  - Australian Government
  - Department of Health
- **Middle East**
  - WHO regional office

**Organizations**
- WHO
- Gavi
- CEPI
- UNICEF
- World Bank
- BMGF
- CSO (incl. MSF)
- IFPMA
- DCVMN
- Academics

**WHO regional offices**

June 8, 2021
### Process and key timeline for COVID Vaccine Global Vision

<table>
<thead>
<tr>
<th>Activity</th>
<th>May</th>
<th>Jun</th>
<th>Jul</th>
<th>Aug</th>
<th>Sep</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milestones</td>
<td>03.</td>
<td>10.</td>
<td>17.</td>
<td>24.</td>
<td>03.</td>
</tr>
<tr>
<td>Weekly Task team</td>
<td>31.</td>
<td>07.</td>
<td>14.</td>
<td>21.</td>
<td>03.</td>
</tr>
<tr>
<td>SAGE COVID-19 WG</td>
<td>02.</td>
<td>09.</td>
<td>16.</td>
<td>23.</td>
<td>30.</td>
</tr>
<tr>
<td>Member States briefing</td>
<td>06.</td>
<td>13.</td>
<td>20.</td>
<td>27.</td>
<td></td>
</tr>
</tbody>
</table>

**Milestones**
- **Technical document finalized**
- **Global goal and framework for action to be launched in near future**

**Living document** with imminent release; the narrative will get refined as new evidence becomes available.
Context and need for coordinated approach to vaccination

**Disease burden**
- 250mn+ cases and nearly 5 million deaths\(^1\) of COVID-19 declared
- Despite rapid Vaccine development, new waves threaten health systems, variants are more transmissible, & serious long-term sequelae reported

**Vaccines as the solution**
- Nearly 6 Bn doses of vaccine already administered
- Global production is now reaching 1.5 billion doses per month
- In areas of high coverage, major reductions in serious disease, hospitalization, death

**Inequities**
- However, the world is not positioned to end the pandemic
- Access is highly inequitable, ranging from 1% to >70%, depending largely on wealth

**Challenges**
- Variants continue to emerge, causing surges of disease & slowing or reversing reopening of societies & economies; with losses potentially >US$9 trillion by 2025\(^2\)

---

\(^1\) reported as of September 2021
\(^2\) IMF estimations
Health and socio-economic goals drive the global COVID-19 vaccination goal

1. as evidence become available
COVID-19 vaccination coverage targets

- **70% coverage target** driven by health & economic imperatives of rapidly stopping the pandemic; technical analyses on epidemiology & vaccine attributes; and feasibility assessment

- **Interim targets of 10% / 40% coverage** to ensure equitable pace of global vaccine rollout & prioritization of those at highest risk

Source: Achieving Global Covid-19 Vaccination by mid-2022 Strategy Brief
Rationale for broad coverage

- Immunization of all adults with COVID-19 vaccines will provide substantial and important health returns on investment, is feasible to achieve in all countries with the right investments, is grounded in evidence and is being actively pursued already in many countries;

- Vaccination of adolescents will further reduce disease burden and provide other important benefits towards resuming socio-economic activity, as impact on reducing transmission is fully investigated;

- At-risk investments needed to assure rapid deployment of vaccines while scientific knowledge advances; building necessary financial infrastructure, supply capacity and delivery services takes time;

- The global COVID-19 vaccination effort can be leveraged to strengthen primary health-care systems and other immunization activities.

Note: This broad vaccination scope is underpinned by a thorough technical and feasibility assessment that analyzed: (i) COVID-19 disease and infection epidemiology, (ii) evolving science on COVID-19 vaccines and SAR CoV-2 virus evolution, (iii) required vaccine doses and global supply, (iv) vaccine and delivery costs, (v) expected health and economic returns on investment, and (vi) political will, financing, supply and programmatic resources.

Source: Achieving Global Covid-19 Vaccination by mid-2022 Strategy Brief
The global COVID-19 vaccination goal and targets are anchored in following principles:

**Equity**
All individuals, populations & countries should have equitable access without financial hardship;

**Quality**
Vaccines used should meet international standards through WHO authorization;

**Integrated**
Vaccines should be deployed with tests, treatments and public health & social measures;

**Inclusivity**
Vaccination must include marginalized, displaced and vulnerable populations.

Source: Achieving Global Covid-19 Vaccination by mid-2022 Strategy Brief
Achieving the global COVID-19 vaccination targets requires anticipating and addressing key challenges:

- Producing an adequate global supply of COVID-19 vaccines
- Ensuring sufficient financial and programmatic resources for procurement & delivery
- Guaranteeing equitable access to COVID-19 vaccines by all countries, across income groups
- Managing risks associated with the emergence of new variants of SARS-CoV-2

Source: Achieving Global Covid-19 Vaccination by mid-2022 Strategy Brief
High-level resource requirements

**Worldwide vaccine need:** 11-12 Bn doses

**Worldwide gap:** 5+ Bn doses *(6 Bn doses administered to date)*

**Vaccine production:** 1.5 Bn doses per month

**LIC/LMIC total funding/financing need:** $55 Bn, but much of the vaccine requirement has already been contracted

**LICs/LMICs in-country delivery costs:** $15-$20 Bn, need to be covered through in-kind, domestic, grants, concessional loans

New ACT-A Strategy/Budget planned for release by 15 Oct with more detail on the gap that should be covered through COVAX
Aligned and coordinated action is needed to achieve the global COVID-19 vaccination targets

All Countries
Establish national plans and commit to equitable vaccine distribution, including free flow of materials and vaccines; thoroughly report local data through eJRF

High Coverage Countries
Take urgent actions to get vaccine doses to lower coverage countries through COVAX, AVAT and other means

CSOs Private Sector
Empower people, communities and partners locally and globally to act in support of demand and equity

WHO, Gavi, UNICEF, CEPI
Ensure COVAX’s success and support end to end impact for equitable, high coverage

MDBs and Institutions
Ensure sufficient delivering funding and support for procurement

Manufacturers
Prioritize supply and transparency to ensure global equity and share know-how

Transparency and data as critical enabler, from manufacturers on ‘place in the queue’, bilateral deals and from countries on accurate and complete data reporting

70%
June 2022

Source: Achieving Global Covid-19 Vaccination by mid-2022 Strategy Brief
Next steps

- Living document
- Public release in the near future
- Continuously discuss with partners & Member States and refine as new evidence becomes available